Phase 3
Completed N=614
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis
Source: ClinicalTrials.gov NCT01465763 ↗Enrolled (actual)
614
Serious AEs
3.4%
Results posted
Jun 2016
Primary outcomePrimary: Percentage of Participants With Remission at Week 8 — 18.5; 8.2 percentage of participants — p=0.0070
◆ Published Evidence
Highly cited
120citations · ~40 / year
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
Summary
This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or be intolerant to one of following treatments for ulcerative colitis: oral steroids, azathiopurine/6-mercaptopurine, or anti-TNF-alpha therapy.
Linked Publications (5)
-
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
-
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.
-
Association Between Smoking Status and the Efficacy and Safety of Tofacitinib in Patients with Ulcerative Colitis.
-
Presence of risk factors associated with colectomy among patients with ulcerative colitis: a <i>post hoc</i> analysis of data from the tofacitinib OCTAVE ulcerative colitis clinical program.
-
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Remission at Week 8 |
18.5; 8.2 | 0.0070 sig |
| SECONDARY Percentage of Participants Achieving Mucosal Healing at Week 8 |
31.3; 15.6 | 0.0005 sig |
| SECONDARY Percentage of Participants Achieving Clinical Response at Week 8 |
59.9; 32.8 | <0.0001 sig |
| SECONDARY Percentage of Participants With Endoscopic Remission at Week 8 |
6.7; 1.6 | 0.0345 sig |
| SECONDARY Percentage of Participants With Clinical Remission at Week 8 |
18.5; 8.2 | 0.0070 sig |
| SECONDARY Percentage of Participants With Symptomatic Remission at Week 8 |
11.8; 5.7 | 0.0601 |
| SECONDARY Percentage of Participants With Deep Remission at Week 8 |
6.5; 0 | 0.0043 sig |
| SECONDARY Partial Mayo Scores |
6.3; 6.5; 4.2; 5.2; 3.5; 4.8 | — |
| SECONDARY Change From Baseline in Partial Mayo Scores at Weeks 2, 4 and 8 |
-2.1; -1.2; -2.8; -1.6; -3.1; -1.6 | <0.0001 sig |
| SECONDARY Change From Baseline in Total Mayo Scores at Week 8 |
9.0; 9.1; -3.8; -1.9 | <0.0001 sig |
Eligibility Criteria
Inclusion Criteria
- Subject must be at least 18 years of age.
- Males and females with a documented diagnosis of UC at least 4 months prior to entry into the study.
- Subjects with moderately to severely active UC based on Mayo score criteria.
- Subjects must have failed or be intolerant of at least one of the following treatments for UC:
- Corticosteroids (oral or intravenous).
- Azathioprine or 6 mercaptopurine (6 MP).
- Anti TNF-alpha therapy.
Exclusion Criteria
- Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease.
- Subjects with disease limited to distal 15 cm.
- Subjects without previous treatment for UC (ie, treatment naïve).
- Subjects displaying clinical signs of fulminant colitis or toxic megacolon.
Data sourced from ClinicalTrials.gov (NCT01465763) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.